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INTRODUCTION
Subclinical hypothyroid (SH) is defined by an elevated
serum thyroid-stimulating hormone (TSH) concentration in
the presence of normal serum thyroid hormone levels. Sub-
clinical thyroid failure is often asymptomatic; nearly 30%
of patients with this condition may have symptoms that are
suggestive of thyroid hormone deficiency (1-3). As in overt
hypothyroidism, patients with SH also shown to be at high
risk for atherosclerosis and cardiovascular disease (4). A high
level of homocysteine (Hcys) in plasma has been proposed
as an independent risk factor for occlusive cardiovascular dis-
ease. The plasma Hcys level is affected by several life-style
and physiological factors and is elevated under the condition
of impaired folate and cobalamin status and in renal failure
(5). There are consistent reports demonstrating that thyroid
status is an important determinant of the plasma concentra-
tion of Hcys (6, 7). 
T4 levels are the determinant of several components of the
fibrinolytic system. T4 has an impact on the synthesis and
catabolism of proteins, and the final modification of serum
levels of these proteins may depend on the severity of the dis-
ease, in hypothyroidism. Chadarevian et al. found that plas-
ma levels of fibrinogen was either correlated to plasma levels
of T4 or altered in patients displaying normal to low free thy-
roxine (FT4) levels or hypothyroidism (7-9). Therefore, we
undertook the present study to investigate the changes of
Hcys and fibrinogen levels undergoing subclinical and overt
hypothyroid patients before and after L-T4 replacement thera-
py and compare them in euthyroid subjects. 
MATERIALS AND METHODS
Fifteen premenopausal women newly diagnosed with SH
(mean age, 41.4±14.1 yr) and 20 overt hypothyroid (mean
age, 41.3±11.1 yr) were enrolled in the study. The cause of
hypothyroidism was chronic autoimmune thyroiditis with
positive anti-TPO antibody. The diagnosis of SH was based
on basal serum TSH values between 5-20 mIU/L and normal
free triiodothyronine (fT3) and fT4 levels. No patient had
received T4 replacement therapy prior to the enrollment in
our study. Obese (body mass index [BMI] >30 kg/m2) sub-
jects, smokers, patients with any major organ or systemic dis-
ease and those using alcohol or any medication known to in-
terfere with thyroid hormone, fibrinogen, and Hcys metabo-
lism were excluded from the study. We also excluded women
with a history of previous thyroid disease, psychiatric disor-
der, or anticipated pregnancy. Each group was also compared
with age- and weight-matched 11 euthyroid premenopausal
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Homocysteine and Fibrinogen Changes with L-thyroxine in Subclinical
Hypothyroid Patients
The aim of the present study was to evaluate plasma total homocysteine (Hcys) and
serum fibrinogen concentrations in subclinical hypothyroid (SH) and overt hypothy-
roid patients before and after L-thyroxine (LT4) replacement and to compare them
in euthyroid subjects. Fifteen SH and 20 hypothyroid premenopausal women were
recruited in the study. We measured fasting plasma levels of Hcys and serum lev-
els of free thyroxine (fT4), free triiodothyronine (fT3), thyrotropin (TSH), folate, vita-
min B12, fibrinogen, renal functions, and lipid profiles in patients with SH and overt
hypothyroid patients before and after LT4 treatment. Eleven healthy women were
included in the study as a control group. Pretreatment Hcys levels were similar in
SH and control subjects, whereas mean fibrinogen level of SH patients was higher
than that of control subjects (p<0.05). Baseline Hcys (p<0.01) and fibrinogen (p<
0.001) levels of the overt hypothyroid patients were significantly higher than those
of the healthy subjects, and the pretreatment Hcys levels decreased with LT4 treat-
ment (p<0.001). In conclusion, our data support that SH is not associated with hyper-
homocysteinemia and Hcys does not appear to contribute to the increased risk for
atherosclerotic disease in patients with SH.
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. . . .healthy women as a control group. 
Blood samples were withdrawn after 12 hr of overnight
fasting, at 08.30 a.m., for serum TSH, fT3, fT4, total choles-
terol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), cre-
atinine, Hcys, folate, vitamin B12, and fibrinogen. Hcys was
measured by high performance liquid chromatography me-
thod (HPLC, Los Angeles, CA, U.S.A.). Folate and vitamin
B12 levels were determined by using Access Immunoassay
system (Sanofi Diagnostics, Pasteur, Paris, France). Fibrino-
gen levels were determined by using coagulometric method
(Multifibren, Dode Behring/BCS, Marburg, Germany). FT3,
fT4, and TSH were measured by enzyme immunoassay (Roche
Diagnostics, Manheim, Germany). Serum TC, HDL-C and
TG were determined enzymatically (Olympus Diagnostica,
Lismeehan, Ireland). LDL-cholesterol (LDL-C) was calculat-
ed with the Friedewald’s formula (LDL-C=TC-[HDL-C+
TG/5]). Serum creatinine was measured by an automated
enzymatic method (Olympus Diagnostica, Ireland) and cre-
atinine clearance (Ccr) was calculated using the Cockcroft
and Gault formula: Ccr (mL/min)=(140-age [yr])×weight
(kg)/(0.81×creatinine [ M/L]). This value was multiplied
by 0.85 for women.
Normal ranges in our laboratory are as follows: TSH, 0.27-
4.01  IU/mL; fT3, 1.8-4.6 pg/mL; fT4, 0.93-1.7 ng/dL; TC,
130-200 mg/dL; TG, 25-160 mg/dL; HDL-C, 39-80 mg/dL;
LDL-C, <130 mg/dL; Folate, >3 ng/mL; Vitamin B12, 145-
914 pg/mL; fibrinogen, 1.8-3.5 g/L; Hcys, 0-15  M/L.
SH and overt hypothyroid patients received replacement
therapy with 100  g of L-thyroxine daily. Dose titration was
adjusted according to the second month’s TSH results. They
took the medicine early in the morning on empty stomach.
Patients were asked not to change their life style (diet or exer-
cise) during the six-month study period. Thyroid function,
Hcys, folate, vitamin B12, fibrinogen, lipid profiles, and renal
functions were measured again after 6 months of stable eu-
thyroidism. No patients were lost to follow-up. The local
ethics committee approved this study, and all the subjects gave
written informed consent.
Statistical analyses including parametric and nonparamet-
ric tests were done with the statistical package for social sci-
ences software (SPSS, version 10.0). Data are presented as
means±standard deviation. A probability value less than
0.05 was accepted as statistically significant. Paired t-test
was used for compairing pre-treatment and post-treatment
values of patients. Student t-test was used for compairing
patients and control group values. Correlation analyses were
performed according to Pearson. Changes of any parameters
(delta) with treatment were analyzed, and correlation analyses
of delta levels were also done.
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Data are mean±SD. Comparison between control group and SH patients
before treatment (*p<0.05, 
� p<0.01, 
� p<0.001). Comparison of SH patients
before and after treatment (
�p<0.05, 
‖p<0.01, 
¶p<0.001). Comparison
between control group and treatment group **p<0.05.
BMI, body mass index; Free T3, free triiodothyronine; Free T4, free thyroxine;
TSH, thyrotropin; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; TC,
total cholesterol; Hcys, homocysteine. 
SH patients
(before 
treatment) 
(n=15)
SH patients
(after treatment)
(n=15)
Control 
subjects (n=11)
Age (yr) 39.9±12.5 41.4±14.1 41.4±14.1
BMI (kg/m
2) 23.6±3.9 26.4±3.3 26.2±3.3
Free  T3 (pg/mL) 2.9±0.6 2.4±0.6 2.7±0.6
‖
Free  T4 (ng/dL) 1.4±0.2 1.0±0.1
� 1.2±0.2
¶
TSH ( IU/mL) 2.2±0.9 15.8±2.4
� 3.4±1.6
¶
Creatinine clearance  114.4±20.7 114.2±24.8 109.8±10.4
(mL/min)
Total cholesterol (mg/dL)192.0±21.3 228.8±56.6* 203.2±39.4
‖
LDL-C (mg/dL) 100.3±11.1** 143.6±45.2
� 127.5±36.8
�
HDL-C (mg/dL) 49.1±8.7 48.5±15.1 45.3±10.8
Triglyceride (mg/dL) 205.5±52.8 161.0±80.5 152.6±77.2
TC/HDL-C 4.0±0.5 4.9±1.2* 4.7±1.3
Folate (ng/mL) 7.2±1.0 6.8±1.5 7.1±1.5
Vitamin B12 (pg/mL) 244.2±47.2 245.1±88.8 238.0±51.0
Hcys ( M/L) 7.9±0.6 9.2±3.3 7.8±2.1
Fibrinogen (g/L) 2.0±0.1** 2.7±1.1* 2.6±0.9
Table 1. Characteristics of subclinical hypothyroid (SH) patients
before and after LT4 therapy and controls
Data are mean±SD. Comparison between control group and overt hy-
pothyroid patients before treatment (*p<0.01, 
� p<0.001). Comparison of
overt hypothyroid patients before and after treatment (
� p<0.05, 
�p<0.001).
Comparison between control group and treatment group 
‖p<0.05, 
¶p<
0.01, **p<0.001.
BMI, body mass index; Free T3, free triiodothyronine; Free T4, free thyroxine;
TSH, thyrotropin; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; TC,
total cholesterol; Hcys, homocysteine. 
Overt
hypothyroid
patients
(before treat-
ment) (n=20)
Overt hypothy-
roid patients
(after treatment)
(n=20)
Control 
subjects 
(n=11)
Age (yr) 39.9±12.5 41.3±11.1 41.3±11.1
BMI (kg/m
2) 23.6±3.9 25.8±3.3 25.5±2.7
Free T3 (pg/mL) 2.9±0.6 2.0±0.9* 2.4±0.8
�
Free T4 (ng/dL) 1.4±0.2
¶ 0.6±0.3
� 1.1±0.4
�
TSH ( IU/mL) 2.2±0.9** 52.8±21.7
� 3.7±1.0
�
Creatinine clearance   114.4±20.7 104.0±21.2 107.0±20.3
(mL/min)
Total cholesterol (mg/dL)192.0±21.3 252.2±67.5
� 200.1±47.5
�
LDL-C (mg/dL) 100.3±11.1
‖ 163.2±49.9
� 124.1±36.0
�
HDL-C (mg/dL) 49.1±8.7 45.7±10.2 42.5±17.1 
Triglyceride (mg/dL) 205.5±52.8 211.3±122.5 185.1±78.3
TC/HDL-C 4.0±0.4
‖ 5.7±1.9
� 5.1±1.7
�
Folate (ng/mL) 7.2±1.0 6.8±1.6 7.0±1.6
Vitamin B12 (pg/mL) 244.2±47.2 236.4±102.0 242.0±119.8
Hcys ( M/L) 7.9±0.6 10.3±3.4* 7.7±2.3
�
Fibrinogen (g/L) 2.0±0.1
¶ 3.3±1.2
� 3.2±1.3
Table 2. Baseline  data of the overt hypothyroid patients and the
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RESULTS
Descriptive characteristics for the control group and the
SH patients both during the initial evaluation and after the
medical treatment are shown in Table 1. Age and BMI val-
ues of the two groups were similar. Before treatment, the
mean TSH level was apparently higher in SH patients ver-
sus the control subjects (15.8±2.4 vs. 2.2±0.9 IU/mL,
p<0.001), and the mean fT4 level was lower in SH patients
than in controls (1.0±0.1 vs. 1.4±0.2 ng/dL; p<0.001).
The fibrinogen level of SH patients was higher than that of
control subjects (2.7±1.1 vs. 2.0±0.1 g/L, p<0.05), where-
as Hcys level was similar. The mean LDL-C, TC level and
TC/HDL-C ratio of SH patients were significantly higher
than those of control subjects (143.6±45.2 vs. 100.3±11.1
mg/dL, p<0.01; 228.8±56.6 vs. 192.0±21.3 mg/dL, p<0.05;
4.9±1.2 vs. 4.0±0.4, p<0.05, respectively).
After treatment of SH patients, the TSH level decreased
(from 15.2±2.4 to 3.4±1.6 IU/mL,  p<0.001) and fT3
and fT4 increased significantly (from 2.4±0.6 to 2.7±0.6
pg/mL, p<0.05; 1.0±0.1 to1.2±0.2, p<0.001, respective-
ly). In addition, TC and LDL-C levels decreased significant-
ly with treatment (228.8±56.6 vs. 203.2±39.4 mg/dL,
p<0.01; 143.6±45.2 vs. 127.5±36.8 mg/dL, p<0.05, res-
pectively). Neither fibrinogen nor Hcys levels of SH patients
changed with treatment. While post-treatment TSH, fT3
and fT4 levels of SH patients were similar to those of control
subjects, the post-treatment LDL-C level of SH patients was
still significantly higher than that of control subjects (127.5
±36.8 vs. 100.3±11.1 mg/dL, p< 0.05) (Table 1). 
The baseline and post-treatment characteristics data of overt
hypothyroid patients and the healthy control groups are sum-
marized in Table 2. Age and BMI values of the two groups
were similar. The pre-treatment TSH level was significantly
higher in-overt hypothyroid group than in healthy subjects
(52.8±21.7 vs. 2.2±0.9 IU/mL,  p<0.001). On the other
hand, fT3 and fT4 levels were significantly lower (2.0±0.9
vs. 2.9±0.6 pg/mL; p<0.01; 0.6±0.3 vs. 1.4±0.2 ng/dL,
p<0.001, respectively). Before treatment, overt hypothyroid
patients had significantly higher Hcys and fibrinogen levels
compared to controls (10.3±3.4 vs. 7.9±0.6 M/L,  p<0.01;
3.3±1.2 vs. 2.0±0.1 g/L, p<0.001, respectively). In addi-
tion, mean TC, LDL-C levels and the TC/HDL-C ratio were
significantly higher in overt hypothyroid subjects than in
healthy controls (252.2±67.5 vs. 192.0±21.3 mg/dL, p<
0.001; 163.2±49.9 vs. 100.3±11.1 mg/dL, p<0.001, 5.7
±1.9 vs. 4.0±0.4, p<0.001, respectively) (Table 2).
After achieving euthyroid state, Hcys levels of overt hypo-
thyroid patients decreased significantly (from 10.3±3.4 to
7.7±2.3 M/L,  p<0.001). Furthermore, TC, LDL-C levels,
and the TC/HDL-C ratio of overt hypothyroid patients were
decreased after gaining euthyroid state (from 252.2±67.5
to 200.1±47.5 mg/dL, p<0.001; from 163.2±49.9 to 124.1
±36.0 mg/dL, p<0.001; 5.7±1.9 to 5.1±1.7, p<0.05,
respectively). Even though all patients’ post-treatment TSH,
fT3, and fT4 levels were in normal limits, post-treatment
TSH level was significantly higher (3.7±1.0 vs. 2.2±0.9
IU/mL, p<0.001) and fT4 (1.1±0.4 vs. 1.4±0.2 ng/dL,
p<0.01) was significantly lower than in control subjects. In
addition, post-treatment fibrinogen (3.2±1.3 vs. 2.0±0.1
g/L, p<0.01), LDL-C (124.1±36.0 vs. 100.3±11.1 mg/dL,
p< 0.05), and the TC/HDL-C ratio (5.1±1.7 vs. 4.0±0.1,
p<0.05) were also significantly higher than in control sub-
jects (Table 2).
Serum vitamin B12, folate, creatinine, and creatinine clear-
ance levels remained unchanged after L-thyroxine treatment
either SH or overt hypothyroid patients.
In overt hypothyroid patients, the changes in Hcys levels
( Hcys) by treatment was negatively correlated with the
changes of folate ( folate) (r=-0.49, p=0.025) and vitamin
B12 ( vitamin B12) (r=-0.45, p=0.044). In addition, there
were positive correlations between  Hcys and  TC (r=0.61,
p=0.004), LDL-C  (r=0.625,  p=0.003), and the  TC/HDL-
C ratio (r=0.546, p=0.013).
Except pre-treatment serum FT4 and TSH, no significant
differences were found between SH and overt hypothyroid
patients in any parameters either before or after treatment.
DISCUSSION
Several reports in the literature indicate that hypothyroi-
dism is associated with elevated plasma Hcys concentrations
(6, 10, 11). Thyroid status has a profound influence on a vari-
ety of biochemical processes, some of which may have sec-
ondary effects on the Hcys metabolism. Thyroid hormones
markedly affect riboflavin metabolism, mainly by stimulat-
ing flavokinase and thereby the synthesis of flavin mononu-
cleotide and flavin adeninedinucleotide (FAD) (12-14). Con-
ceivably, these metabolic changes may affect Hcys metabo-
lism because flavin mononucleotide and FAD serve as cofac-
tors for enzymes involved in the metabolism of vitamin B6,
cobalamin, and folate (14). Circulating Hcys concentrations
in hypothyroidism can rise through reduced activity of the
flavoprotein methylenetetrahydrofolate reductase (MTHFR),
an enzyme involved in the catalysis of Hcys and its remethy-
lation to methionine. Hypothyroid individuals can be defec-
tive in converting riboflavin to the co-enzyme FAD, and con-
sequently, deficient in MTHFR activity (15).
Increased Hcys levels in hypothyroid patients might con-
tribute to a higher cardiovascular risk (13). It has been shown
that thyroid replacement in such patients’ results in lower-
ing of the Hcys level. Whether or not individuals with SH
also increase their Hcys concentrations, and whether this ele-
vation might help to explain the increased prevalence of athe-
rosclerotic diseases observed in this condition, remain unclear.
If an elevation in serum Hcys concentrations with associated
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in individuals with SH, this would provide an added impe-
tus to identify and treat this disorder with thyroid replace-
ment therapy (16-18). 
Luboshitzky et al. compared 57 women with SH against
34 healthy controls and found no significant increase in Hcys
levels in SH subjects (19). In addition, Atabek et al. investi-
gated Hcys concentrations in adolescent patients with SH.
Hcys concentrations showed no statistical difference between
patients and controls in their study (20). Furthermore, Deich-
er et al. measured plasma Hcys levels in newly diagnosed SH
patients at baseline and after three months of L-T4 supple-
mentation. Hcys levels remained unchanged. They proposed
that Hcys was not associated with an increased risk for ische-
mic heart disease in SH patients (21).
Sengul et al. evaluated Hcys levels and the effect of L-thy-
roxine treatment in SH. After L-thyroxine treatment, Hcys
levels reduced significantly. They reported that if Hcys was
elevated, treatment of SH with L-thyroxine might decrease
the risk of coronary artery disease (22). On the other hand,
Perez et al. investigated the impact of euthyrodism restora-
tion on emerging risk factors including Hcys, C-reactive pro-
tein, and apolipoprotein B in SH patients. No treatment effect
was observed on these emerging risk factors in patients with
TSH >10 mIU/L. They proposed that measurement of emerg-
ing risk factors did not offer additional arguments for treat-
ing patients with a TSH level >10 mIU/L (23). In addition,
Ozcan et al. evaluated Hcys levels in SH patients. No differ-
ence were found in Hcys levels between patients and control
group, and no changes were noted in plasma Hcys concentra-
tions after treatment (24). This result is similar to our results.
Elevated levels of fibrinogen have consistently shown as
an independent predictor of initial and recurrent cardiovas-
cular events (25). There are several potential mechanisms by
which fibrinogen can promote the development of atheros-
clerosis and thrombosis (25, 26). It affects the haemostatic
system and is the major determinant of plasma viscosity. Fib-
rinogen is an acute phase reactant and therefore could also be
a marker for increased inflammatory activity (27). Canturk
et al. measured fibrinolytic activity in 35 SH patients before
and after L-T4 treatment and found a significantly higher
fibrinogen level in SH patients than in healthy controls. How-
ever, no significant beneficial effect of LT4 treatment to fib-
rinogen levels was seen in patients with SH (3). The result
was based on the number of study population and the rela-
tively short period of treatment. Muller et al. investigated
various haemostatic variables in 42 women with SH and com-
pared them to 66 euthyroid controls. They found no differ-
ences between the groups with respect to fibrinogen (28). In
our study, we observed higher fibrinogen levels in SH patients
than in control subjects, but fibrinogen levels remained un-
changed with L-T4 treatment as was observed in Canturk’s
study.
Hypothyroidism is associated with high cholesterol and
lipoprotein levels (29). Treatment of hypothyroid patients
with L-thyroxine normalizes lipid levels (4, 30). The associ-
ation of SH with changes in serum lipid levels and the effect
of T4 replacement on these changes are still elusive. Arem
and Patsch demonstrated that HDL-C, HDL3-C, and apoli-
poprotein A-1 were not significantly affected by levothyrox-
ine therapy and there was only a slight trend of increase in
HDL2-C besides a significant reduction in LDL-C during T4
substitution in SH patients with a mean TSH level of 16.6
IU/mL (31). On the other hand, Caron et al. reported lower
HDL-C levels in SH patients than in a control group and
demonstrated a significant increase in HDL-C levels after
levothyroxine therapy (32). However, a controlled trial includ-
ing 66 women with SH found no significant change in HDL-
C (33). Serter et al. found higher pre-treatment serum TC
and LDL-C concentrations in SH patients than in control
subjects and reduced TC, LDL-C and TC/HDL-C ratio after
LT4 replacement therapy (34). Our results found similar to
those from the Serter’s study.
In our study, patients with overt hypothyroidism have high-
er Hcys and fibrinogen levels than healthy subjects. Hcys
level of overt hypothyroid patients decreased with LT4 treat-
ment. There was a negative correlation between  Hcys and
folate, and  vitamin B12 levels in overt hypothyroid pati-
ents. Elevated Hcys levels in overt hypothyroidism may be
linked to altered folate and vitamine B12 status. In contrast
to overt hypothyroidism, only fibrinogen, but not Hcys val-
ues, was affected in SH, yet without significant improvement
after L-thyroxine therapy. We conclude that SH is not asso-
ciated with hyperhomocysteinemia and atherosclerosis seen
in SH patients might be due to higher fibrinogen and athe-
rogenic lipid profiles. 
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